Drug Profile
Mesenchymal stem cell therapies - Cytopeutics
Alternative Names: Autologous mesenchymal stem cell therapiesLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Cytopeutics
- Developer Cytopeutics; National University of Malaysia
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cartilage replacements; Cell replacements; Osteogenesis stimulants; Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Dilated cardiomyopathy
Most Recent Events
- 05 Sep 2017 Discontinued - Phase-II for Dilated cardiomyopathy in Malaysia (Intracoronary)
- 01 Jul 2014 No recent reports on development identified - Phase-II for Dilated cardiomyopathy in Malaysia (Intracoronary)
- 01 Jul 2012 Phase-II clinical trials in Dilated cardiomyopathy in Malaysia (Intracoronary) (NCT01720888)